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ABSTRACT 
 
Background 
Diffuse parenchymal lung diseases (DPLD) encompass a group of diseases with a wide range 
of causes with varied presentations and prognosis.  The known causes include occupational or 
environmental exposure, drug induced lung diseases, hypersensitivity pneumonitis and 
connective tissue disease (CTD). Among the DPLD with unknown cause, idiopathic pulmonary 
fibrosis (IPF) is the commonest and has the worst outcome. The earlier publications from this 
country described cryptogenic fibrosing alveolitis. With subsequent characterisation of 
idiopathic interstitial pneumonia (IIP), and an increase in the burden of IPF reported worldwide, 
we evaluated the clinical features of patients with IPF in the South African context.  
 
Objectives 
To evaluate the clinical spectrum of DPLD encountered in Johannesburg, South Africa, and to 
describe the clinical profile of patients with IPF. 
 
Methods 
A retrospective record review of patient files was conducted who attended the Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) Respiratory Clinic in the past 5 years 
from January 2011 to December 2015. Patients with DPLD were identified and the diagnoses 
were noted. The records of patients with IPF were further analysed. 
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Results  
We identified 132 patients with DPLD. Sarcoidosis (37.8%), IPF (21.2%), connective tissue 
associated diffuse parenchymal lung disease (CTD-DPLD) (14.3%), and hypersensitivity 
pneumonitis (HP) (9.8%) were the four most common subtypes. IPF was seen in all racial 
groups. Of the 28 patients with IPF in our cohort, there was a slight female predominance 
(1.3:1). The mean age of the patients in our study was 63.8 years and the majority were Whites. 
Cough (96.4%), dyspnoea (92.8%) and bilateral crackles (96.4%) were the commonest clinical 
features. The majority of patients (78.5%) were diagnosed by high resolution computerised 
tomography (HRCT) scan.  
 
Conclusion  
IPF is the second most common DPLD disease encountered after sarcoidosis at the CMJAH. 
IPF is seen in all racial groups in Johannesburg, South Africa, and the characteristics of patients 
with IPF are similar to those seen in other parts of the world. 
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ABSTRACT 
 
Background 
Diffuse parenchymal lung diseases (DPLD) encompass a group of diseases with a wide range 
of causes with varied presentations and prognosis.  The known causes include occupational or 
environmental exposure, drug induced lung diseases, hypersensitivity pneumonitis and 
connective tissue disease (CTD). Among the DPLD with unknown cause, idiopathic pulmonary 
fibrosis (IPF) is the commonest and has the worst outcome. The earlier publications from this 
country described cryptogenic fibrosing alveolitis. With subsequent characterisation of 
idiopathic interstitial pneumonia (IIP), and an increase in the burden of IPF reported worldwide, 
we evaluated the clinical features of patients with IPF in the South African context.  
 
Objectives 
To evaluate the clinical spectrum of DPLD encountered in Johannesburg, South Africa, and to 
describe the clinical profile of patients with IPF. 
 
Methods 
A retrospective record review of patient files was conducted who attended the Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) Respiratory Clinic in the past 5 years 
from January 2011 to December 2015. Patients with DPLD were identified and the diagnoses 
were noted. The records of patients with IPF were further analysed. 
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Results  
We identified 132 patients with DPLD. Sarcoidosis (37.8%), IPF (21.2%), connective tissue 
associated diffuse parenchymal lung disease (CTD-DPLD) (14.3%), and hypersensitivity 
pneumonitis (HP) (9.8%) were the four most common subtypes. IPF was seen in all racial 
groups. Of the 28 patients with IPF in our cohort, there was a slight female predominance 
(1.3:1). The mean age of the patients in our study was 63.8 years and the majority were Whites. 
Cough (96.4%), dyspnoea (92.8%) and bilateral crackles (96.4%) were the commonest clinical 
features. The majority of patients (78.5%) were diagnosed by high resolution computerised 
tomography (HRCT) scan.  
 
Conclusion  
IPF is the second most common DPLD disease encountered after sarcoidosis at the CMJAH. 
IPF is seen in all racial groups in Johannesburg, South Africa, and the characteristics of patients 
with IPF are similar to those seen in other parts of the world. 
  
 CHAPTER ONE: PROTOCOL WITH EXTENDED LITERATURE REVIEW 
 
1.1 Introduction 
Diffuse parenchymal lung diseases (DPLD) comprise a group of diseases with a wide range of 
causes that are characterized by diffuse infiltration of the lungs.(1,2) In these diseases there is 
inflammation and fibrosis of alveoli, distal airways and pulmonary septal interstitium causing 
substantial morbidity and mortality.(2,3) The fibrotic changes in the lung parenchyma are 
usually progressive.(5) A similar pattern of inflammation and fibrosis may result from different 
causes of lung injury.(3) Therefore, these categories of diseases may have similar clinical, 
radiological, physiologic and/or histopathological features.(6) Lung biopsy assists with 
differentiating between the different histopathological patterns and the overall clinical 
diagnosis is done through incorporation of clinical, radiological and histopathological 
features.(3) 
 
1.2. Classification of DPLD 
DPLD can be broadly classified into exposure related, connective tissue disease associated 
diffuse parenchymal lung disease (CTD-DPLD), idiopathic interstitial pneumonitis (IIP), 
granulomatous lung disease and other miscellaneous group of lung diseases (Figure 1, adapted 
from reference 7).(7,8)  
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Figure 1. Classification of DPLD 
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1.3 Clinical features of DPLD 
DPLD usually presents with progressive shortness of breath, audible crackles on lung 
auscultation and the chest radiograph may show diffuse lung infiltrates in advanced disease.(3) 
Symptoms are due to the development of inflammatory and fibrotic lung changes with 
attenuated gaseous exchange and arterial hypoxaemia.(9) Digital clubbing and coarse “Velcro” 
crackles may be heard on auscultation.(9) There seem to be a correlation between long standing 
disease and pulmonary arterial pressures.(9) Lung function tests in most of the patients may 
show a restrictive pattern with reduced diffusion capacity for carbon monoxide (DLCO).(10) 
Reductions in DLCO are characteristic of parenchymal lung diseases and its blood supply.(3) 
Diagnosis of DPLD requires a combination of clinical, radiological and/or histopathological 
examination and discussion amongst the various disciplines.(11) Differential diagnoses include 
other conditions such as pulmonary oedema, infective pneumonia and malignancy.(3) Further 
investigations such as echocardiography may be required to exclude other possible 
diagnoses.(3)  
 
1.4 Exposure and environmental related DPLD 
Exposure to toxic substances, for example mining dust, may affect the lungs. The association 
between occupational lung disease and mining has been noted since the early 1500’s.(12) 
Asbestosis, silicosis and coal worker’s pneumoconiosis (CWP) are of huge public and 
occupational health concern.(12) Coal dust causes pneumoconiosis in the form of simple CWP 
and progressive massive fibrosis (PMF).(13) Controlling and preventing asbestos-related lung 
complications are known public health issues and several countries, including South Africa, 
have banned manufacturing, processing, importing or exporting of asbestos.(12) South Africa 
was the fifth largest supplier of chrysotile in the world.(12) Owing to previous extensive use, 
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there are many possible sources for asbestos exposure. (12) Despite negligible asbestos mining 
exposure, people may still be exposed to asbestos through removal of asbestos-containing 
products such as ceiling boards.(12) Pulmonary fibrosis with asbestos exposure makes the 
diagnosis of asbestosis likely.(12) High resolution computerized tomography (HRCT) scan 
frequently demonstrates parenchymal fibrosis with pleural plaques.(12) In silicosis, the dust 
burden exposure is the main determinant of disease.(14) Silicosis increases the risk of 
tuberculosis (TB).(14) Prevalence of silicosis, HIV and TB is known to be extremely high in 
South African gold miners.(14) 
 
1.5 Drug induced DPLD 
Drug-induced lung injury may involve all the compartments, including small and large airways, 
lung parenchyma, mediastinal structures, pleura, and pulmonary vessels.(10) The commonest 
type of drug-related lung toxicity is drug-induced interstitial lung disease (DILD).(10) The 
clinical, radiological and histopathological findings of DILD are non-specific and therefore, 
diagnosis of DILD is not straight forward.(15) Diagnosis of DILD is largely dependent on a 
definite temporal relationship between exposure to the drug and the onset of respiratory 
symptoms and signs.(15) Nearly all the histopathological subtypes of DPLD may be seen 
including, acute interstitial pneumonia (AIP) or diffuse alveolar damage (DAD), usual 
interstitial pneumonia (UIP), lymphoid interstitial pneumonia (LIP), non-specific interstitial 
pneumonia (NSIP), desquamative interstitial pneumonia (DIP), organizing pneumonia (OP), 
eosinophilic pneumonia (EP), hypersensitivity pneumonitis (HP) and granulomatous lung 
disease.(10) DILD may be caused by cytotoxic drugs (bleomycin), cardiovascular drugs 
(amiodarone, beta-blockers, hydrochlorothiazide), anti-inflammatory agents (non-steroidal 
anti-inflammatories, methotrexate, sulphasalazine), antimicrobials (isoniazid, amphotericin B) 
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and  biological agents (rituximab, bevacizumab).(15) Some drugs, however, may produce 
stereotypical histopathological reaction in the lungs. For example, methotrexate induces acute 
granulomatous lung disease; minocycline induces EP and nitrofurantoin induces cellular type 
of NSIP.(10) DILD may present with signs ranging from minimal infiltrates to acute respiratory 
distress syndrome (ARDS) that could be life threatening.(10) The likelihood of developing 
drug-induced lung injury remain mostly random and idiosyncratic.(7,10) Patients with chronic 
inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease 
(IBD) and those on cancer chemotherapy are at increased risk of developing DILD.(15) This 
may also be related to other factors such as smoking.(9) 
 
1.6 Hypersensitivity pneumonitis 
Hypersensitivity pneumonitis (HP) is a complex immunological response syndrome caused by 
exposure to various organic particles.(16) Fungi, bacteria, protozoal, animal and insect proteins 
and other chemical compounds are some of the causative agents.(16) The prevalence of HP 
varies around the world depending on the definition of HP, host genetic risk factors, method 
used for diagnosis, nature of exposure, geographical conditions, agricultural and industrial 
practices.(16) The clinical presentation is similar despite various antigens being responsible for 
the development of HP and has been conventionally classified into acute, subacute, and chronic 
forms.(16,17) This classification, however, is now being challenged and a set of clinical 
predictors has been proposed.(17) 
 
1.7 Connective tissue disease associated DPLD 
 
6 
Connective tissue diseases (CTD) or autoimmune diseases are a diverse group of immune 
mediated systemic inflammatory diseases that frequently target the lungs.(16) DPLD is 
common in many of these disorders including scleroderma or systemic sclerosis (SS),  RA, 
systemic lupus erythematosus (SLE) and inflammatory myopathies.(16) DPLD may be the first 
sign of a connective tissue disorder.(11) A study reported that 3.5% of patients were diagnosed 
with DPLD before they were diagnosed with RA.(11) DPLD may occur in all connective tissue 
disorders, with an estimated incidence of 15%.(11) This justifies excluding autoimmune 
conditions in patients with suspected idiopathic DPLD.(11) In RA, DPLD is the commonest  
and potentially most devastating extra-articular manifestation.(11) The long term prognosis of 
patients with connective tissue disorder complicated by DPLD has recently been shown to be 
less severe than that of IPF.(8,9) DPLD as a complication of RA affects twice as many men as 
women.(11) Besides cardiac disease, DPLD is the next most common cause of mortality in RA 
and is estimated to be between ten and twenty percent.(8,9) The most frequent histological 
patterns seen in CTD-DPLD include NSIP and UIP.(11) Organizing pneumonia may occur in 
polymyositis (PM) and RA.(11) LIP is mostly found in Sjögren’s syndrome and RA and usually 
responds to corticosteroids.(11) DAD or AIP is seen in RA, PM, SLE and undifferentiated 
CTD.(11) Psoriasis, an auto-immune skin condition, is a rare cause of DPLD. 
 
1.8 Smoking related DPLD 
Smoking-related DPLD comprises a heterogeneous group of conditions which have 
traditionally been viewed as individual entities.(18) These disorders frequently co-exist with 
the main common sequelae of cigarette smoking-induced injury such as chronic obstructive 
pulmonary disease (COPD) and bronchogenic carcinoma.(18) Traditionally there are DPLD 
related to smoking namely, respiratory bronchiolitis–associated interstitial lung disease (RB-
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ILD), DIP, and pulmonary Langerhans cell histiocytosis (PLCH).(18) These types of DPLD 
are seen in current and former smokers. There may also be deterioration of lung function in 
spite of smoking cessation.(18) Smoking has also been associated with poor outcome in other 
DPLD that are not usually associated with smoking, like RA.(18) Cigarette smoking is a known 
risk factor for the development of IPF or UIP.(18)  
 
1.9 Human immunodeficiency virus associated DPLD 
Patients infected with human immunodeficiency virus (HIV) are at an increased risk for 
opportunistic infections and non-infectious lung complications such as DPLD.(19,20) The 
various HIV-related DPLD have no clear unifying aetiology. It is thought that DPLD may occur 
as a result of immune dysregulation and/or reconstitution as well as some associated co-
infections.(20) LIP is characterized by an influx of lymphocytes into the alveolar space. HIV-
infected patients in several studies have normal airways at baseline but the DLCO was seen to 
be diminishing over time.(19,20) NSIP and LIP are manifestations of immune dysregulation 
and their frequency has declined significantly due to availability of antiretroviral treatment 
(ART).(20) 
 
1.10 Sarcoidosis 
Sarcoidosis is a systemic condition characterized by the development of non-caseating 
granulomas.(17) Sarcoidosis affects different organs such as the eyes, skin, nervous system, 
lymph nodes, bone marrow, liver and blood. The clinical presentation depends mostly on the 
organ involved.(18) Sarcoidosis typically affects younger adults and has predilection for 
lungs.(19) In countries with high TB prevalence such as South Africa, sarcoidosis is often 
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misdiagnosed as TB as the two diseases have similar clinical, radiological and pathological 
features.(20)  
 
1.11 Other DPLD 
Other rare causes of DPLD are lymphangioleiomyomatosis (LAM), PLCH, EP, vasculitis, and 
neurofibromatosis.(7,8)  LAM and PLCH are rare conditions characterised by the presence of 
pulmonary parenchymal cysts.(21) Diffuse alveolar haemorrhage (DAH) may be a 
manifestation of pulmonary vasculitis.(22) DAH is usually seen in small-vessel vasculitides, 
namely microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).(22) It 
may also be associated with Goodpasture’s syndrome, Henoch Schönlein purpura and SLE.(22) 
EP include a spectrum of lung diseases that may present with peripheral blood eosinophilia 
(>0.5×109/L) and/or alveolar eosinophilia (>25%).(23) Drugs and parasitic infections are some 
of the causes of eosinophilic pneumonia.(23) However, chronic EP remains largely 
idiopathic.(23) Pulmonary alveolar proteinosis (PAP) is a rare diffuse lung disease 
characterised by alveoli filling with proteinaceous material.(11) 
 
2.0 Idiopathic interstitial pneumonitis 
The idiopathic interstitial pneumonitis (IIP) are a subset of DPLD without a known cause.(24) 
As illustrated in figure 1, they are classified into the IPF and non-IPF groups. The non-IPF 
group can be further subdivided histologically into NSIP, DIP, cryptogenic organizing 
pneumonia (COP), RB-ILD, AIP and LIP.(18,19) It is vital to exclude known causes of DPLD. 
The diagnosis of IIP requires exclusion of known causes of DPLD such as drugs, inhalational 
exposure or HP and CTD.(25) While the term ‘idiopathic’ specifies the lack of a known 
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causative factor, there is much postulation as to the pathogenesis of these disorders.(26) 
Cigarette smoking is a risk factor in the pathogenesis of IIP.(26) Furthermore, smoking is 
believed to have a significant role in the development and progression of IPF.(26) 
 
2.1 Idiopathic pulmonary fibrosis 
The most common and deadly subtype of IIP is IPF.(27) The term IPF is now applied 
exclusively to the syndrome associated with the morphological pattern of UIP.(2) Patients with 
IPF are usually in their sixth decade at presentation and men are affected slightly more often 
than women.(2) The median survival from diagnosis varies between 2 to 5 years.(2) 
 
2.1.1 Epidemiology 
This subtype of IIP is considered rare, however, it seems to be increasingly reported with 
greater frequency worldwide.(28) Incidence of IPF varies across the world. Lower incidence 
has been reported in Asia and Southern America where it ranges from 0.5 to 4.2 per 100 000 
people per year.(28) Europe and North America have higher incidence between 2.8 and 18 
cases per 100 000 people per year.(29) No studies have reported the incidence of IPF in Africa 
or South Africa.  
 
2.1.2 Aetiology 
The aetiology of IPF is not known. It is thought that many factors are involved in its 
pathogenesis.(28) Interaction between genetics and environmental factors with recurrent local 
damage to ageing alveolar epithelium play a significant role.(28) Aberrant epithelial-fibroblast 
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interaction, induction of matrix-producing myofibroblasts with marked extracellular matrix 
accumulation and remodeling of lung interstitium is the result of these micro-injuries.(28) 
There is also maladaptive repair process involving dysregulation of type 2 pneumocytes which 
is believed to be crucial to fibrogenesis in IPF.(28) 
 
2.1.3 Clinical presentation 
The presentation of IPF is usually insidious over a period of at least 3 months.(30) Symptoms 
are usually non-specific. These include dyspnoea on exertion which may be accompanied by 
dry cough.(28) These may initially be attributed to other conditions such as obesity, ageing, 
emphysema and cardiovascular diseases.(28) On clinical examination, patients usually have 
digital clubbing with bibasilar late inspiratory “Velcro” crackles.(28) Other known causes of 
DPLD such as CTD-DPLD, exposure related DPLD, sarcoidosis and other IIP should be 
excluded with detailed history, clinical examination and investigations.(28,30) Lung function 
tests show restrictive impairment of varying extent depending on disease stage.(30) DLCO is 
typically remarkably impaired.(30) The above typical lung function tests may be different in 
combined pulmonary fibrosis and emphysema (CPFE) where lung volumes are preserved but 
with significant diminished DLCO and the ratio of FEV1/FVC may either be normal or 
demonstrate an obstructive ventilatory pattern.(30) 
 
2.1.4 Diagnosis 
Clinical suspicion is important in patients over the age of 50 that present with insidious onset 
of exertional dyspnoea with or without cough.(28) An experienced multidisciplinary team 
should be responsible for making the diagnosis of IPF on clinical and radiological findings with 
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or without histological confirmation.(30) Chest radiograph is an important initial investigation 
to direct further investigations into the underlying diagnosis.(19) However, this investigation 
is neither specific nor sensitive.(19) The standard investigation in patients suspected to have 
IPF or any DPLD is HRCT.(19,30) HRCT is often the only special investigation necessary to 
make a definitive diagnosis of IPF which shows typical radiological UIP pattern.(30) However, 
other causes of UIP should be excluded.(30) This may have significant therapeutic and 
prognostic implication.(27) If the HRCT scan is not conclusive or if the patient presents with 
atypical clinical and radiological features, lung biopsy should be performed.(30) Patients that 
are regarded as unsuitable for surgical lung biopsy can be assessed as IPF based on the opinion 
of the experienced multidisciplinary team.(30)    
 
The typical features of UIP on HRCT are interlobular septal thickening, reticular opacities and 
traction bronchiectasis, predominantly bilateral, peripheral, and basal in distribution. In 
addition there are clusters of subpleural, cystic airspaces with honeycombing and absent or 
minimal ground glass opacities. These typical radiographic features confirm the diagnosis of 
IPF and if present it is usually not necessary to perform a surgical lung biopsy.(2,27) 
 
The histological feature of IPF is a UIP pattern. This includes temporal and spatial 
heterogeneity within the same biopsy i.e., areas of normal looking lung alternating with 
interstitial fibrosis, fibroblastic foci, architectural distortion and honeycombing with minimal 
or no inflammation.(25,28) 
 
2.1.5 Treatment 
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2.1.5.1 Immunomodulatory drugs 
A Cochrane review exploring the efficacy of corticosteroid in the treatment of adults with IPF  
did not find any eligible studies.(31) Azathioprine is an immunosuppressant that blocks the 
function of proliferating cells such as T-cells and B-cells.(32) The use of azathioprine and 
prednisone demonstrated an improvement in lung volumes and gaseous exchange in a small 
retrospective study performed in 1978.(32) This was also analysed in a prospective randomised 
double blind controlled study by Raghu et al in 1991, where azathioprine and prednisone vs. 
prednisone alone were compared and found that there was a trend towards survival benefit.(33) 
However, it did not reach statistical significance. Cyclophosphamide, a cytotoxic 
chemotherapy agent, in combination with prednisone has been evaluated in 2 retrospective 
studies.(34,35) One showed survival benefit in patients with early disease while the other 
showed no difference.  
 
2.1.5.2 N-acetyl cysteine 
The PANTHER-IPF and another randomized double-blind placebo controlled study showed 
that a triple combination of azathioprine, prednisone and N-Acetyl cysteine (NAC) was 
associated with greater mortality (11% vs 1%), more hospitalization (29% vs 8%) and more 
serious side effects (31% vs 9%).(36,37) These side effects were not observed with either the 
dual therapy or with NAC alone. The triple regimen also, did not show any difference in lung 
function. There was no significant benefit observed with NAC alone compared with 
placebo.(37) However, in the IFIGENIA study, it was found that the triple regimen had 
favourable outcome compared to the standard treatment of azathioprine plus prednisone as 
evidenced by slower decline in FVC and DLCO.(38) The investigators, however, did not 
conclude on the side effects associated with the triple regimen. In addition, they also did not 
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have a group of patients on NAC alone and therefore it was unknown whether NAC alone 
would be associated with better outcome compared to placebo or other drug regimen. 
 
2.1.5.3 Antacid therapy 
Many studies have documented the co-existence of gastro-oesophageal reflux disease (GORD) 
and IPF.(33,34,35) Raghu et al. have shown that 87% of their study patients had GORD and 
53% of these patients were asymptomatic.(34) In the recent post-hoc analysis of antacid therapy 
in three trials of pirfenidone (CAPACITY 004, CAPACITY 006 AND ASCEND), antacid 
therapy was not associated with better rates for mortality or decrease in FVC.(40) Hospital 
admissions were not lower. In fact, hospital admissions were non-significantly higher. Side 
effects were similar between treatment and placebo groups. Overall infections and pulmonary 
infections were found to be higher with the antacid group in patients with advanced disease.  
 
2.1.5.4 Anti-fibrotic agents 
Recently, two new oral anti-fibrotic agents have approval for the treatment of IPF. Pirfenidone 
is an anti-fibrotic drug with anti-oxidant and anti-inflammatory properties.(40,41) The efficacy 
of pirfenidone in IPF has been mixed.(30) In the ASCEND study, pirfenidone, was found to 
reduce the decline in 6-minute walk distance and also progression free survival. The decline in 
FVC was also significantly reduced as compared with placebo.(42) CAPACITY trials also 
found reduction in decline in FVC and an increase in progression free survival and there was 
increase in oxygen saturation on the treatment group.(40,41). Nintedanib is a drug that inhibits 
receptor tyrosine kinases.(19) This drug was shown by 2 studies INPULSIS-1 and INPULSIS-
2 with identical designs to significantly lower the annual rate of change in FVC compared to 
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placebo.(43) A difference of 125ml and 94ml annually was demonstrated in the INPULSIS-1 
and INPULSIS-2 clinical trials respectively. In INPULSIS-1, however, no difference between 
the nintedanib and placebo groups in the time to the first acute exacerbation of IPF was found. 
The Food and Drug Administration (FDA) approved nintedanib for the treatment of IPF on 
October 2014. Both pirfenidone and nintedanib are not registered in South Africa. They can, 
however, be obtained through section 21 order.(30) The South African Thoracic Society 
recommends that these drugs be offered to patients with IPF with FVC 50-80%.(30) However, 
treatment should be stopped if FVC declines by at least 10%. This is an indication of disease 
progression.(30) 
 
2.1.5.5 Lung transplantation 
At the current moment, lung transplantation is the only intervention that improves survival in 
select patients with IPF.(44) One year post transplant, survival was increased by 79% in a study 
of 46 patients awaiting transplant.(45) Data from the international society for heart and lung 
transplantation has demonstrated that between January 2000 and June 2005, one and five year 
survival rates for single lung transplant (SLT) in IPF were 76% and 45% and for bilateral lung 
transplant (BLT) were 77% and 52% respectively.(46) This form of treatment is difficult to 
access as there are limited resources in the public sector and long-term post-transplant care is 
also a challenge in South Africa.(30) 
 
3.0 Study aims and objectives 
3.1 Aims 
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The aim of this study is to document the clinical profile of patients with IPF seen at the Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) Respiratory Clinic. In addition we aim to 
record the spectrum of DPLD encountered.  
 
3.2 Objectives 
1. To document and study the clinical profile of patients with IPF attending the CMJAH 
Respiratory Clinic. 
2. To determine the causes and spectrum of diffuse parenchymal lung disease encountered. 
 
3.3 Methods 
3.3.1 Study design 
Retrospective record review  
 
3.3.2 Study population 
Patients with diffuse parenchymal lung disease attending the respiratory outpatient department 
at the CMJAH in the last 5 years will be identified. The clinical profile of patients with a 
diagnosis of IPF will be studied. 
 
3.3.2.1 Site and size of study  
The study will take place at CMJAH Respiratory Clinic. CMJAH is a tertiary hospital situated 
in Parktown, Johannesburg, South Africa. It has 1088 usable bed and is one of the 3 main 
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teaching hospitals in Johannesburg affiliated to the University of the Witwatersrand. It also 
serves as a referral centre for a number of hospitals in its drainage area in and around the 
Gauteng province. There are approximately 70 to 100 patients that attend the CMJAH 
respiratory clinic on a weekly basis. These include both new and old patients. Patients 
diagnosed with DPLD in the last 5 years, January 2011 to December 2015, will be documented 
and the records of those patients with IPF will be evaluated. 
 
3.3.2.2 Measurements and observations 
Medical records of patients who attended CMJAH pulmonology OPD will be reviewed for the 
diagnosis of diffuse parenchymal lung disease. Those with a diagnosis of IPF will be studied. 
Data will be collected for these patients attending the clinic in the last 5 years (January 2011 to 
December 2015). Files will be reviewed and a data collection sheet will be utilised to record 
data obtained from the files. Patient names will be replaced by numbers to protect patient 
confidentiality. Clinical, radiographic and laboratory data will be recorded and analysed 
 
3.3.2.3 Inclusion criteria 
Those patients with diffuse parenchymal lung disease with a diagnosis of IPF attending 
Respiratory Clinic at CMJAH 
 
3.3.2.4 Exclusion criteria 
Patients whose diagnoses are unclear 
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3.3.2.5 Limitations or potential problems 
Data collection from files may not always be present or complete. 
 
3.4 Data analysis 
The data will be collected using a data collection sheet, and will be analysed using STATA 
version13.  For data management a spreadsheet will be used. Categorical variables will be 
expressed using frequency distribution. Continuous data will be expressed using descriptive 
statistics such as mean, standard deviation, median and range. The assistance of a statistician 
will be used to interpret the data collected. 
 
3.5 Ethics 
Ethics approval shall be obtained from the Human Research Ethics Committee of the University 
of the Witwatersrand as well as the University's Postgraduate Committee before 
commencement of the study. Permission will also be obtained from the hospital management 
of CMJAH. 
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3.6 Timing 
 Jul  
2015 
Aug 
2015 
Sep  
2015 
Oct  
2015 
Nov  
2015 
Dec 
2015 
Jan 
2016 
Feb  
2016 
Mar 
2016 
Apr 
2016 
May 
2016 
Jun 
2016 
Literature 
review 
            
Preparing 
protocol 
            
Protocol 
assessment 
            
Ethics 
application 
            
Collecting 
data 
            
Data 
analysis 
            
Writing up             
 
 
3.7 Funding 
No costs are anticipated other than that necessary for stationery, photocopying, printing, and 
binding which will be covered by myself.  
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ABSTRACT 
 
Background 
Diffuse parenchymal lung diseases (DPLD) encompass a group of diseases with a wide range 
of causes with varied presentations and prognosis.  The known causes include occupational or 
environmental exposure, drug induced lung diseases, hypersensitivity pneumonitis and 
connective tissue disease (CTD). Among the DPLD with unknown cause, idiopathic pulmonary 
fibrosis (IPF) is the commonest and has the worst outcome. The earlier publications from this 
country described cryptogenic fibrosing alveolitis. With subsequent characterisation of 
idiopathic interstitial pneumonia (IIP), and an increase in the burden of IPF reported worldwide, 
we evaluated the clinical features of patients with IPF in the South African context.  
 
Objectives 
To evaluate the clinical spectrum of DPLD encountered in Johannesburg, South Africa, and to 
describe the clinical profile of patients with IPF. 
 
Methods 
A retrospective record review of patient files was conducted who attended the Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) Respiratory Clinic in the past 5 years 
from January 2011 to December 2015. Patients with DPLD were identified and the diagnoses 
were noted. The records of patients with IPF were further analysed. 
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Results  
We identified 132 patients with DPLD. Sarcoidosis (37.8%), IPF (21.2%), connective tissue 
associated diffuse parenchymal lung disease (CTD-DPLD) (14.3%), and hypersensitivity 
pneumonitis (HP) (9.8%) were the four most common subtypes. IPF was seen in all racial 
groups. Of the 28 patients with IPF in our cohort, there was a slight female predominance 
(1.3:1). The mean age of the patients in our study was 63.8 years and the majority were Whites. 
Cough (96.4%), dyspnoea (92.8%) and bilateral crackles (96.4%) were the commonest clinical 
features. The majority of patients (78.5%) were diagnosed by high resolution computerised 
tomography (HRCT) scan.  
 
Conclusion  
IPF is the second most common DPLD disease encountered after sarcoidosis at the CMJAH. 
IPF is seen in all racial groups in Johannesburg, South Africa, and the characteristics of patients 
with IPF are similar to those seen in other parts of the world. 
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Introduction 
Diffuse parenchymal lung diseases (DPLD) encompass a wide spectrum of disorders, with 
varied presentations and prognosis.(1–3) DPLD can be broadly classified into exposure related, 
connective tissue disease associated interstitial lung disease (CTD-ILD), idiopathic interstitial 
pneumonia (IIP), granulomatous lung disease and other miscellaneous group of lung 
diseases.(1,4) The known causes include occupational or environmental exposure, drug 
induced lung diseases, hypersensitivity pneumonitis and connective tissue disease (CTD).(7,8) 
Among the DPLD with unknown cause, idiopathic pulmonary fibrosis (IPF) is the commonest 
and has the worst outcome.(5,6) The earlier publications from this country described 
cryptogenic fibrosing alveolitis.(7,8) With subsequent characterisation of idiopathic interstitial 
pneumonia (IIP), and an increase in the burden of IPF reported worldwide(2,6,9,10) we 
evaluated the clinical features of patients with IPF in the South African setting There is a lack 
of published data in South Africa regarding, prevalence, presentation, management and 
outcomes of IPF. 
 
Aim 
The aim of this study was to evaluate the clinical profile of patients with IPF at the Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) Respiratory Clinic. In addition, we aimed 
to record the spectrum of DPLD encountered at the Clinic. 
 
Materials and Methods 
We retrospectively reviewed records at CMJAH Respiratory Clinic over a 5 year period, from 
January 2011 to December 2015. All patient records were perused and patients with DPLD 
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were identified. Patients with DPLD were further divided into different diagnoses and patients 
with IPF were included in the study if they were 18 years and older. In addition, they had to 
have adequate records which at a minimum, had to have IPF as their diagnosis and a high 
resolution CT scan and/or lung biopsy results. Approval for the study was obtained from the 
Hospital administration and the Human Research Ethics Committee of the University of the 
Witwatersrand. 
 
Results 
One hundred and thirty two patients with diffuse parenchymal lung disease (DPLD) were 
identified. Sarcoidosis, IPF, CTD-ILD, and HP were the four most common DPLD subtypes in 
our population. As shown in Table 1, fifty (37.8%) patients were diagnosed with sarcoidosis, 
the commonest DPLD encountered, and twenty-eight (21.2%) patients were diagnosed with 
idiopathic pulmonary fibrosis (IPF), the second most common DPLD seen in the study. CTD-
ILD was seen in 19 (14.3%) patients and HP in 13 (9.8%) patients. The records of the patients 
with IPF were further analysed.  
 
Of the 28 patients that were diagnosed with IPF, 12 were males (42.8%) and 16 females 
(57.1%), ratio of males to females was 1:1.3. The mean age of the cohort of patients was 63.8 
years. Whites comprised 42.8% of the patients, 29.5% were Black, 25% Indian and 1 patient 
was a Coloured female. The sex ratio was equal among the Whites and 1.7 times more common 
in the Black males than the female patients. There were 6 females and 1 male among the Indian 
patients. The majority, 27 (96.4%) patients, were over of the age of 50. Ten (35.7%) patients 
were older than 70 years old. The youngest patient was 47 years old (Table 2 and Figure 2). 
 
29 
 
Seventeen (60.7%) patients were either current or ex-smokers. In seven patients there was 
information regarding the amount and duration of cigarettes smoked and the average pack-
years was 20. One patient was an underground gold-miner. 
 
Cough was the most common presenting symptom in 27 (96.4%) patients followed by dyspnoea 
in 26 (92.8%) patients while chest pain was present in only 1 (3.5%) patient. Bibasilar crackles 
were found in almost all patients (96.4%), central cyanosis in 13 (46.4%) patients and clubbing 
in 12 (42.8%) patients, respectively (Table 4). 
 
Coexistent diseases that were seen in these patients are listed in Table 5. Pulmonary 
hypertension was present in 12 (42.8%) patients, systemic hypertension in 8 (28.5%) patients, 
followed by chronic obstructive pulmonary disease (COPD) (14.2%), gastro-oesophageal 
reflux disease (GORD) (7.1%) and hypothyroidism (7.1%). Two (7.1%) patients were HIV-
positive and the CD4+ was 580 and 98/µL respectively. Other diseases that were present 
included aortic stenosis, diabetes mellitus, breast cancer and osteoporosis (in 4 different 
patients). 
 
Six (21.4%) patients had surgical lung biopsies. Of the 6 patients, 5 patients had a confirmed 
usual interstitial pneumonia (UIP)-pattern on histology and one patient had a suspected chronic 
HP. After comprehensive review of the HRCT scan, histopathology and clinical parameters the 
patient was deemed to have IPF and treated as such. The anti-nuclear antibody (ANA) was 
positive in low titre (≤1:128) in 5 (17.8%) patients with IPF. (Table 6) 
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Twenty two (78.5%) patients were diagnosed as having IPF by HRCT scan with the typical 
features of UIP. Interlobular septal thickening, reticular opacities associated with traction 
bronchiectasis, predominantly bilateral, peripheral, and basal distribution, clusters of 
subpleural, cystic airspaces of similar diameters with honeycombing and absent or minimal 
ground glass opacities are the typical radiographic features of UIP. Four (14.2%) patients had 
combined pulmonary fibrosis and emphysema (CPFE). 
 
The lung functions (Table 7) demonstrates that the forced expiratory volume in 1 second 
(FEV1) was decreased in 17 patients; between 60-80% predicted in 11 patients and between 
40-59% predicted in 6 patients. The FVC was normal in 10 patient and decreased in 18 patients; 
between 60-80% predicted in 12 patients and between 40-59% predicted in 6 patients. The 
mean FVC percent predicted ± SD was 74 ± 17. None of the patients had an obstructive defect 
i.e. FEV1/FVC ratio below 70%. The total lung capacity (TLC) was decreased in 16 patients 
(13 between 60-80% predicted and 3 between 40-59% predicted). The mean TLC percent 
predicted ± SD was 76 ± 12. Ten patients had a RV/TLC ratio > 50% predicted of whom 4 had 
RV/TLC >100% predicted. The diffusion capacity for carbon monoxide (DLCO) was 
decreased in all 25 patients in whom it was measured; between 60-80% predicted in 3, between 
40-59% in 8 and <40% predicted in 14 patients. The mean DLCO percent predicted ± SD was 
37 ± 18. 
 
Ten (35.7%) patients were treated with corticosteroids (CS) alone. Six of these patients were 
on CS for an average of 30 months. Eight (28.5%) patients were on azathioprine (AZA) alone, 
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half of whom were on it for approximately twenty-six months. Five (17.8%) patients received 
N-Acetylcysteine (NAC) alone. Three (10.7%) patients were treated with a triple drug regimen 
consisting of CS, AZA and NAC. These patients were younger age 50, 54 and 58 years 
respectively. The durations of follow up for these patients were 36, 48 and 36 months 
respectively. One patient was treated with a combination of CS and NAC. (Table 8) 
 
Only 1 patient, who had medical insurance, was referred for assessment for lung transplantation 
at a private facility, during the study period. This patient was a 66 year old female with a 5 
pack-year smoking history. She was seen at the clinic for 2 months and was referred for lung 
transplantation. The outcome of this patient is not known. 
 
Nine (32.1%) patients received domiciliary oxygen therapy. The average duration of follow-up 
of these patients was 27.4 months. Four patients were on diuretics for right heart failure 
secondary to cor pulmonale. Three patients received therapy for GORD (2 patients received 
omeprazole and 1 patient ranitidine). 
 
Eleven (39.2%) patients were known to be still alive and attending the clinic while the other 17 
(60.7%) patients did not return for follow-up clinic visits. 
 
Discussion 
Spectrum of DPLD seen at CMJAH 
IPF is the second most common DPLD encountered at the CMJAH Respiratory Clinic after 
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sarcoidosis, which is the commonest. 
 
Gender  
In the United States of America, males had a higher incidence of IPF than females. Higher 
incidences were also observed among males in Europe.(11) In Norway, however, females had 
higher incidence of IPF compared to males 4.6 vs 4.0 per 10,000 person years.(12) IPF may 
also progress faster in men and result in worse survival.(13) Our study showed a slight female 
predominance (1.3:1), though small study number. 
 
Age and Race 
IPF was prevalent in all racial groups. IPF is more commonly seen in patients between the ages 
of 40 and 70.(14) Raghu et al reported higher IPF prevalence among older males of 65 years 
or older. (15) A similar trend was observed in a European study.(12) In general, IPF prevalence 
increases with age, with highest prevalence in patients over the age of 75 years with no clear 
sex predominance.(16) In a study done in Hillbrow Hospital, Johannesburg, South Africa, by 
Smith et al. in 1990, Blacks had a similar clinical spectrum to other groups in other parts of the 
world.(7) The mean age of the patients in our study was 63.8 and Whites predominated 
compared to other races. The mean ages in the different population groups in Whites, Blacks 
Indians and Coloureds were 64, 60, 67, and 78 years, respectively. 
 
Smoking  
Smoking is thought to play a significant role in the pathogenesis, development and progression 
 
33 
of IPF.(9) Smith et al showed that cigarette smoking was associated with a worse outcome.(7) 
In the current study more than half of the patients were either current or ex-smokers. There 
were no differences in the lung functions (TLC and DLCO) between smokers and non-smokers. 
Four patients in our study had CPFE on HRCT scan. 
 
Symptom and signs 
Cough, dyspnoea and bilateral crackles were present in 96.4%, 92.8% and 96.4% of patients 
respectively. Cyanosis was noted in 46.4% and clubbing in 42.8% of patients. This correlates 
with many other studies (10-13).  Of note, there were no skin lesions present in patients with 
IPF in the current study.  
 
Comorbid diseases 
As IPF is a disease of older adults, a number of other coexisting conditions may be present in 
these patients, as was seen in this cohort. Pulmonary hypertension was documented in 42.8% 
of the study patients, which may be a marker of severity of disease, as was suggested by 
others.(6,7) GORD may be a comorbid disease in these patients and has also been implicated 
in IPF exacerbations. It is important to diagnose and treat these comorbid conditions as this 
may impact on the patient’s quality of life. 
 
Diagnosis 
In a Swedish study by Giovanni et al, the diagnosis of IPF was mostly based on clinical and 
radiological features and only 10% of the patients underwent invasive procedures such as lung 
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biopsy.(11) In the current study most (78.5%) of the patients were diagnosed by HRCT scan 
that had typical features of UIP.  Six patients (21.4%) had surgical lung biopsies to confirm the 
diagnosis. This was consistent with the data reported in the literature.(17).  
 
Lung function tests 
The FVC was decreased in 18 patients and TLC was decreased in 16 patients, which are typical 
of a restrictive defect. None of the patients had an obstructive defect. The DLCO was decreased 
in all 25 patients in whom it was measured. Ideally the DLCO should be measured in all patients 
(if facilities are available) suspected of having IPF, as it may have diagnostic and prognostic 
implications.(18) 
 
Treatment  
Due to the small number of the study population, retrospective nature of the study, and 
unavailability of some data, analysis of the treatment options and outcome could not be 
ascertained and accurately analysed.  
 
Limitations 
This study had numerous limitations. Firstly, missing information plagues the retrospective 
design. Some findings are difficult to interpret and to compare with other centres due to the 
small study population size and variations in patient characteristics. Patients with autoimmune 
or connective tissue disease attend the Rheumatology Clinic at our institution and not 
necessarily the Respiratory Clinic. Therefore, our study may underestimate the number of cases 
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of CTD-DPLD. In addition, a substantial proportion of patients did not return for their follow-
up clinic visits. Whether these patients were deceased or not, could not be ascertained from the 
records.  
 
Conclusions 
IPF is the second most common DPLD disease encountered after sarcoidosis at the CMJAH. It 
is prevalent in all racial groups in Johannesburg, South Africa. This study showed similar trends 
to those reported in other parts of the world with regard to age of onset, White race 
predominance and the survival rates of patients with IPF. We did not, however, observe the 
higher incidence reported in males. We had a slight female preponderance, as was observed in 
the Norwegian study. 
 
Future direction 
Despite the limitations of this study, our findings add valuable clinical and epidemiological 
information to the paucity of data that exists for IPF in Africa and South Africa. In the future, 
we plan to conduct a prospective study identifying and evaluating the prevalence, clinical 
profile and outcome of patients with this devastating disease. 
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Table 1. Aetiology of diffuse parenchymal lung disease 
 
Spectrum of DPLD (n=132) Number of cases (%) 
  
Sarcoidosis 50 (37.8) 
Idiopathic pulmonary fibrosis (IPF) 28 (21.2) 
Connective tissue disease associated ILD (CTD-ILD) 19 (14.3) 
Hypersensitivity pneumonitis (HP) 13 (9.8) 
Silicosis and progressive massive fibrosis (PMF) 3 (2.2) 
Cryptogenic organising pneumonia (COP) 2 (1.5) 
Desquamative interstitial pneumonitis (DIP) 2 (1.5) 
Lymphoid interstitial pneumonia (LIP) 2 (1.5) 
Pulmonary alveolar proteinosis (PAP) 2 (1.5) 
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) 1 (0.7) 
Psoriasis 1 (0.7) 
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Table 2. Demographic data of IPF patients (n=28) 
 
Demographic Data  
  
Mean Age ± SD (range) 63.86 ± 11.02 (47-78) 
Male: Female 12 (42.8):16 (57.1) 
Age > 50 years No. (%) 27 (96.4) 
Racial breakdown (W:B:I:C) 12:8:7:1 
  
  
W-Whites, B-Blacks, I-Indians, C-Coloureds  
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Table 3. Clinical parameters of patients with IPF 
 
Clinical Features Number of cases (%) 
  
Smoking history  
Smoker or ex-smoker * 17 (60.7)  
  
Occupation  
Gold miner 1 (3.5) 
  
Symptoms  
Cough 27 (96.4) 
Dyspnoea 26 (92.8) 
Chest pain 1 (3.5) 
 
Signs 
Bilateral crackles 
Cyanosis 
 
 
27 (96.4) 
13 (46.4) 
Clubbing 12 (42.8) 
  
Skin lesions 0 (0) 
  
 
*mean pack years ± SD, (range); 20 ± 19.1, (4-55)  
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Table 4. Comorbid diseases in IPF patients 
 
Comorbid Diseases Number of cases (%) 
  
Pulmonary hypertension 12 (42.8) 
Hypertension 8 (28.5) 
Chronic obstructive pulmonary disease (COPD) 4 (14.2) 
Gastroesophageal reflux disease (GORD) 2 (7.1) 
Hypothyroidism 2 (7.1) 
Human immunodeficiency virus infection 2 (7.1) (CD4+ = 580 and 98/μL) 
Aortic stenosis 1 (3.5) 
Diabetes mellitus 1 (3.5) 
Breast cancer 1 (3.5) 
Osteoporosis 1 (3.5) 
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Table 5. HRCT, surgical and serum markers 
 
HRCT, surgical and serum markers Number of cases (%) 
  
HRCT  
HRCT typical features of UIP 22 (78.5) 
CPFE (IPF and emphysema) 4 (14.2) 
  
Surgical lung biopsy 6 (21.4)* 
  
Serum markers  
ANA positive 5 (17.8) 
  
  
HRCT  High resolution computerised tomography scan 
 
*One patient was suspicious for possible hypersensitivity pneumonitis, but eventually 
diagnosed as idiopathic pulmonary fibrosis 
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Table 6. Pulmonary function tests of IPF patients 
 
Pulmonary functions  
  
FEV1 n=28 
  
>80% predicted 11 
60-80% predicted 12 
40-59% predicted 5 
  
Forced Vital Capacity n=28 
  
>80% predicted 10 
60-80% predicted 12 
40-59% predicted 6 
  
Ratio of FEV1/FVC n=28 
  
>90% 9 
70-90% predicted 19 
<70% predicted 0 
  
TLC n=26 
  
>80% predicted 10 
60-80% predicted 13 
40-59% predicted 3 
  
RV/TLC n=25 
  
>100% predicted 4 
>50%-100% predicted 6 
30-50% predicted 15 
  
DLCO n=25 
  
60-80% predicted 3 
40-59% predicted 8 
<40% predicted 14 
  
  
FEV1 Forced expiratory volume in 1 second 
FVC Forced vital capacity 
TLC Total lung capacity 
RV Residual volume 
DLCO Diffusion capacity for carbon monoxide 
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Table 7. Therapy and outcome of IPF patients 
 
Therapy Number of cases (%) 
  
CS (mean duration 30 months) 10 (35.7)  
AZA (mean duration 26 months) 8 (28.5)  
NAC 5 (17.8) 
CS + AZA + NAC (mean duration 40 months) 3 (10.7)  
CS + NAC 1 (3.5) 
  
Long term oxygen therapy (mean duration 27 months) 9 (32.1)  
  
Furosemide (cor pulmonale and right heart failure) 4 (14.2) 
  
Antacid therapy [omeprazole (2) and ranitidine(1)] 3 (10.7) 
  
Lung transplantation referral  1 (3.5) 
  
  
Outcome  
  
Returned for follow up 11 (39.2) 
Did not return for follow up (presumed deceased) 17 (60.7) 
  
  
CS Corticosteroids 
AZA Azathioprine 
NAC N-acetylcysteine 
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CHAPTER 3: APPENDICES 
 
3.1 Data collection sheet (study number) 
 
A. DEMOGRAPHICS AND HISTORY 
1. Gender  Male   
 Female   
2. Age    
3. Race   
4. Smoker Yes   
 No  
5. Occupational history 
 
  
6. HIV status Negative   
 Positive   
6.1. If on ARVs Durations   
6.2. Name of ARVs  
 
 
 
 CD4  
 VL  
7. Other medical conditions 
 
  
8. Drug history  
 
 
 
 
9. CTD Yes   
 No   
9.1. If yes, specify  
 
 
9.2. Treatment of  CTD 
 
 
  
B. SYMPTOMS  
1.Cough   
2.Dyspnoea   
3.Chest pain   
C. SIGNS  
1.Clubbling   
2.Cyanosis   
3.Crackles   
4.Pulmonary Hypertension    
5.Skin lesions   
Other organ involvement    
D. INVESTIGATIONS 
1. Chest X-ray   
2. Lung Function Test   
FEV1   
FVC   
FEV1/FVC   
TLC   
DLCO   
RV/TLC   
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3. HRCT scan results   
4. Lung biopsy results 
4.1. Transbronchial lung biopsy 
4.2. Open lung biopsy 
 
  
5. FBC WCC                          
 Hb  
 HCT  
 PLT  
Differential count Neutrophils  
 Lymphocytes  
 Eosinophils  
 Basophils  
 Other  
6. U&E   
7. Calcium   
8. CRP   
9. ESR   
10. RF   
11. ANA   
12. SCL 70 (DNA topoisomerase)   
13. ANCA   
14. ACE   
15. Other bloods   
 E. TREATMENT 
1. Corticosteroids and duration   
2. Other immunosuppressive drugs 
and duration 
  
3. Other treatment Rx e.g. PPI   
4. Home oxygen   
5. Lung transplant referral 
    Lung transplant done/not 
  
6. Months or Years of follow up   
7. Dead or Alive   
8. Cause of death   
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3.2 Ethics approval certificate 
 
